|
|
Home > Healthcare > Pharmaceutical > General Pharmaceutical
Primary Immune Deficiencies - An Overview
|
| Published Date:
October 2002
Published By:
Datamonitor
Page Count:
32
Order Code:
R313-4440
|
|
|
|
Overview
Introduction
Primary immune deficiencies are inborn genetic defects in the immune system. It is estimated that at least half a million people worldwide suffer from at least one of these disorders. These patients suffer from recurrent and persistent infections. Gene therapy offers the promise of a potential cure, obliterating the need for antibiotic and immunoglobulin therapy and bone marrow transplants.
Scope
Examines disease etiology, symptoms and treatment options available to patients
Looks at the prevalence and diagnosis of some of the more common and defined conditions and discusses the prognosis for these individuals
Assesses unmet needs in the treatment of primary immune deficiencies and future opportunities, particularly in the area of gene therapy
Report Highlights
Prompt administration of antibiotics at the first signs of infection is vital and those with deficient antibody levels require monthly immunogobulin infusions. Bone marrow transplantation has provided complete remission to some suffering from very severe conditions, such as severe combined immunodeficiency disease (SCID), but global success rates over the past thirty years are only between 60-70%. Gene therapy is beginning to show some promise as a viable treatment alternative. The obvious benefit in curing these debilitating illnesses will have to be balanced with the potential risks posed by this new form of treatment. Although entry into the commercial arena is not expected for another few years, the market and growth for gene therapy products will be unprecedented, since application of this technology will have far-reaching implications for a number of other clinical conditions.
Reasons to Purchase
Insightful overview of the key features of primary immune deficiencies, including prevalence, diagnosis and symptoms
Analyse current treatment options and prognosis for some of the more defined and common disorders
Identify unmet needs and learn about future opportunities, especially in gene therapy, which has enormous market potential
DRIVERS AND TRENDS
Primary immune deficiencies, of which there are approximately 90 different forms, are inborn genetic defects in the immune system. It is estimated that at least half a million people worldwide suffer from at least one of these largely incurable disorders. These patients suffer from recurrent and persistent infections. Bone marrow transplantation has provided complete remission to some suffering from very severe conditions, such as severe combined immunodeficiency disease (SCID), but global success rates over the past thirty years are only between 60-70%. Although still a few years from the first commercial product, gene therapy offers the real promise of a viable treatment alternative, thereby obliterating the need for current treatments including life—long antibiotic and immunoglobulin therapy.
INTRODUCTION TO PRIMARY IMMUNE DEFICIENCIES
Future challenges and opportunities in the treatment of primary immune deficiencies are assessed. Very recently, calls have been made that some gene therapy clinical trials, which had been suspended due to adverse side-effects, be re-instigated. This highlights the desperate need for a cure for these conditions.
A complete overview of primary immune deficiencies is provided, detailing prevalence, disease etiology, as well as current and experimental treatments.
IN-DEPTH ANALYSIS OF SOME OF THE MORE DEFINED OR COMMON DISORDERS
B-Cell (antibody) Deficiencies
T-Cell Deficiencies
Combined B- and T-Cell Deficiencies
Phagocytic Deficiencies
|
Similar Products
• United States Type 2 Diabetes Market
Published Nov 2009 by Intellent
• Snapshots Poland Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots Venezuela Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots Spain Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots South Africa Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots Hungary Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Nigeria Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Kenya Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Company Financials: Bayer AG
Published Nov 2009 by Datamonitor
• Merck & Co. Performance, Products, Pipeline and Potential
Published Nov 2009 by Espicom Healthcare Intelligence
|
|
|
|
0 items
